This Small Business Innovation Research Phase I project develops a system for facilitating the monoclonal antibody screening process. The system will be a proprietary technology able to significantly shorten the time required for producing antibody-generating hybridomas, and to improve the successful rate for identifying and cloning monoclonal antibodies. The goal is to establish a cellular basis selection system in collaboration with researchers at Hunter College of the City University of New York.
The broader impacts of this research are in monoclonal antibody generation and production. Since monoclonal antibody has become a powerful tool for diagnosis, treatment and many other purposes in the bioresearch fields, the proposed technology would be of benefit to biotech industry, biodefense against bioterrorism, pharmaceutical industry, and society as a whole. This project also fosters collaboration between industrial biotech and academe.
